menu search

IOVA / Iovance: November PDUFA, But A History Of Delays And Underwhelming Data

Iovance: November PDUFA, But A History Of Delays And Underwhelming Data
Iovance Biotherapeutics, Inc. has a deep pipeline of cancer immunotherapies, but has faced delays and issues with duration of response. The company's lead asset, lifileucel, is being tested in multiple trials for different indications. Underwhelming data from a phase 2 study and poor duration of response in other trials have hurt Iovance Biotherapeutics stock. Read More
Posted: Aug 30 2023, 16:01
Author Name: Seeking Alpha
Views: 112396

IOVA News  

Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer's (SITC) 38th Annual Meeting

By GlobeNewsWire
October 31, 2023

Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer's (SITC) 38th Annual Meeting

SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, dev more_horizontal

Iovance Biotherapeutics: Testing Shareholders' Patience

By Seeking Alpha
October 22, 2023

Iovance Biotherapeutics: Testing Shareholders' Patience

Iovance Biotherapeutics is on the cusp of its first FDA approval for its TIL therapy in the treatment of metastatic melanoma. The company operates on more_horizontal

Iovance Biotherapeutics: Good Trade Setup Created By The FDA Delay Gets Even Better

By Seeking Alpha
October 19, 2023

Iovance Biotherapeutics: Good Trade Setup Created By The FDA Delay Gets Even Better

Iovance Biotherapeutics: Good Trade Setup Created By The FDA Delay Gets Even Better more_horizontal

Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer's (SITC) 38th Annual Meeting

By GlobeNewsWire
September 27, 2023

Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer's (SITC) 38th Annual Meeting

SAN CARLOS, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, de more_horizontal

Iovance Biotherapeutics: Navigates Regulatory Delays With Strategic Finesse (Rating Upgrade)

By Seeking Alpha
September 18, 2023

Iovance Biotherapeutics: Navigates Regulatory Delays With Strategic Finesse (Rating Upgrade)

Iovance Biotherapeutics shows promise in T-cell therapies for solid tumors despite FDA delays; robust financials with a cash runway of 13.1 months. In more_horizontal

Why Shares of Iovance Biotherapeutics Jumped Monday

By The Motley Fool
September 18, 2023

Why Shares of Iovance Biotherapeutics Jumped Monday

Iovance's lead therapy lifileucel still has a chance at an early approval to treat advanced melanoma. Lifileucel is also being tested to treat several more_horizontal

Why Iovance Biotherapeutics Stock Rocketed 13% Higher Today

By The Motley Fool
September 15, 2023

Why Iovance Biotherapeutics Stock Rocketed 13% Higher Today

At first glance, the latest regulatory news is a setback. However, there were more than a few silver linings in this development. more_horizontal

IOVA stock price soared but risk/reward is unfavourable for now

By Invezz
September 15, 2023

IOVA stock price soared but risk/reward is unfavourable for now

Iovance Biotherapeutics (NASDAQ: IOVA) stock price defied gravity on Friday as investors cheered the latest FDA update about its drug. The shares jump more_horizontal


Search within

Pages Search Results: